Kornimate/medical-research-clean huggingface dataset:
effects of transcutaneous electrical nerve stimulation in post-operative lung cancer

Conditions: Cancer, Lung

Summary: among all cancers, lung cancer is the most common disease on the planet, accounting for 13% of the cases, and leading the number of deaths from malignant diseases. in brazil, it is estimated that its incidence between 2018 and 2019 could be 18,704 new cases in men and 12,503,000 new cases in women. these data take into account an estimated risk of 18.16 new cases for 100,000 men and 11.81 for 100,000 women, respectively occupying the second and fourth most frequent cases of the disease according to gender . surgeries, however aggressive they may be, are one of the most viable alternatives for patients with pc, provided it is performed in the milder or early phase of the disease, since after such period this procedure may have a period degree greater than the other forms of treatment. as a consequence, the injuries that the surgical procedure can cause to patients, pain is one of the most influential in the patient's quality of life. it can lead the individual to a marked state of disability both functional and psychological, thus being determinant for the suffering related to the disease, thus comprising its multifactorial character, involving physical, emotional, socio-cultural and environmental aspects . for the control of pain, physiotherapy appears with features such as transcutaneous nerve electrostimulation, where its use for the suppression of pain has become quite feasible due mainly to the ease of its handling, to be noninvasive and to serve to reduce acute pain and chronic. the use of conventional transcutaneous nerve electrostimulation to support the use of analgesics reduced the intensity of pain in patients of the second day of thoracotomy, but for a longer extension of their effects, it would take a longer time to apply the resource, something around 24 -48 hours.


Eligibility criteria:
inclusion criteria: * patients diagnosed with primary lung cancer; male over 18 years and less than 59 years old, in an immediate postoperative period in the ward of the hospital thoracic clinic. * evaluation of pain through the visual analogue scale equal to or greater than moderate or intense. * percentage equal to or greater than 70% in all the items assessed by the performance status functional capacity scale. exclusion criteria: * patients with immediate postoperative complications * unconscious or sedation patients * patients with invasive mechanical ventilation * patients who present lesions that make it difficult to handle and place electrodes. * patients who use pacemakers and metal plates.
impact of hepatitis c virus variability on steatosis

Conditions: Chronic Hepatitis C

Summary: chronic infection by the hepatitis c virus (hcv) is a common cause of liver disease, which may progress to cirrhosis and eventually liver cancer. the therapeutic indication will depend mainly on the importance of liver damage (fibrosis), which can be assessed by physical techniques, blood tests and a liver biopsy. the overall objectives of the project are to understand how hcv variability may influence the severity of steatosis (accumulation of fat in the liver), studying 30 patients chronically infected with hcv (half of these patients infected by hcv genotype 3, versus the other half infected by hcv of another genotype). a small portion of the biopsy performed for the routine pathology examination will be placed in special fixation buffer for electron microscopy (em). counting and measuring the size of lipid droplets present in the liver by em will be used to precisely quantify and characterize the liver steatosis. a blood sample of patients will also be collected to sequence the viral genome present in the patient and identify the amino acids involved in an increase in intracellular accumulation of lipid droplets. this work should clarify the impact of the viral variability in the severity of steatosis. ultimately, the identification of viral sequences responsible for an increase of this phenomenon could be crucial for understanding the mechanisms involved in the steatosis.


Eligibility criteria:
inclusion criteria: * patients with chronic hepatitis c, naive of an antiviral treatment or after relapse or non-response for an antiviral treatment stopped for more than 1 year * liver biopsy necessary for the care of the patient * signature of informed consent exclusion criteria: * patients for which the liver biopsy is estimated ≤ 18 mm, so a portion of 3 mm could not be devoted for the study
evaluation of long-term sequelae after thrombophlebitis, i.e. deep venous thrombosis of the lower extremities

Conditions: Deep Venous Thrombosis

Summary: the purpose of the study was to evaluate efficacy and safety of the new acute treatment of deep venous thrombosis by use of low-molecular-weight heparin compared with standard treatment using unfractionated heparin, especially concerning long-term morbidity.

deep-venous thrombosis (dvt) remains a common clinical problem (annual incidence 0.10-0.16%) and long-term morbidity as chronic venous insufficience (cvi) in 10-30%. as to recurrent dvt, initial treatment with low-molecular-weight heparin ( to-day's terminology fractionated heparin (fh)) and unfractionated heparin (ufh) has shown equal efficiency, whereas the efficacy concerning long-term morbidity has only more recently been published. this study was initiated to compare the efficacy of ufh and fh concerning the incidence of cvi after symptomatic dvt at short-term and long-term follow-up.

Eligibility criteria:
inclusion criteria: * first dvt with or without known risk factors except overt cancer * second dvt more than two years after the first if the patient was without clinical signs of cvi. exclusion criteria: * contraindication to anticoagulation therapy * candidate to thrombectomy with arterious-venous fistula or thrombolytic therapy * known cancer at the time of the dvt diagnosis * patients unable to cooperate for anticoagulation therapy or manage the tests.

Keywords: deep venous thrombosis lower extremities chronic venous insufficiency postthrombotic syndrome heparins low-molecular- weight heparin tinzaparin
the association between pulmonary function tests and difficult airway

Conditions: Airway Obstruction

Summary: the airflow moving from mouth to the lungs, which can be measured by pulmonary function tests, may be affected by the anatomic disorders of the upper airway. difficult airway can be considered as the anatomic disorder of the upper airway as well. therefore, there can be a relationship between difficult airway and pulmonary function tests. the purpose of this study is to elucidate the association between the pulmonary function tests and difficult airway.

after approval of the gaziosmanpasa university clinical trials ethics committee, patients those admitted to the anesthesiology outpatient unit will informed about the study. and pulmonary function tests by using spirodoc® will be performed to those willing to participate in the study. measurements of the pulmonary function tests, and measurements belong to difficult airway will be recorded. in the operating theatre, after induction of anesthesia, the difficult intubation measurements will be recorded. normality and variance will be tested using one sample kolmogorov-smirnov test, skewness, kurtosis and histograms for each variable. quantitative data will present as means and standard deviation, and qualitative data as frequency and percentage. depending on these results, spearman's correlation analysis will perform to show the association between pulmonary function tests and difficult airway measurements. analyses were conducted using the statistical package for social sciences program (spss inc., chicago, il), version 20.0. statistical significance for all analyses was set at p \< 0.05.

Eligibility criteria:
inclusion criteria: * patients whose admitted to the gaziosmanpasa university, medical faculty, anesthesiology and reanimation outpatient unit * patients whose will be planned to undertake a surgical operation under general anesthesia and those performed tracheal intubation to secure the airway. * an american society of anesthesiologists score of 1 or 2 exclusion criteria: * patient whose planned to undertake a surgical operation in the departments of ear-nose-throat, cardiac and vascular surgery, plastic and reconstructive surgery * patients with a history of chronic obstructive lung diseases * patients with a history of surgery on the neck * patients with a history of mandibular surgery

Keywords: airway management intubation pulmonary function test
game-based intervention to promote hpv vaccination

Conditions: HPV Infection; Vaccine-Preventable Diseases

Summary: this study will examine the feasibility and acceptability of an innovative game-based intervention designed for families of youth aged 11-14 to promote hpv vaccination; will explore changes in key outcomes and related measures; and will identify factors contributing to or impeding effective implementation in health clinic settings. the intervention and its approach have the potential to reduce health disparities in hpv-associated cancers in youth via low-cost technology and timely intervention.

guided by social cognitive theory, we propose to 1. examine the feasibility and acceptability of a new hpv preventive intervention, the hpv detective video game, designed for youth and their parents; 2. explore pre-post, intervention-related change in vaccine intent and uptake as well as change in theoretically posited intervention mediators; and 3. assess the potential for broader intervention implementation. using a sequential mixed-methods, 2-group (intervention vs usual care), longitudinal design, 64 parent-youth dyads (32/per study condition) will be recruited. parent-youth dyads in the intervention will play hpv detective (tablet format) at the clinic prior to the healthcare provider visits. the control dyads will receive standard clinic treatment.

Eligibility criteria:
inclusion criteria: * youth: (1) 11-14 years old; (2) have not received the 1st dose of hpv vaccine; (3) speak and read english * parent: (1) are the parent/legal guardian of the participating child; (2) ≥ 18 years old; (3) speak english or spanish; (4) own a smartphone; (5) agree to participate in the research activities at study sites; (6) agree to receive text messages. * healthcare providers: (1) ≥ 20 years old; (2) speak english or spanish); (3) work at study sites exclusion criteria: * individuals are unable to comprehend the consent or assent forms due to cognitive issues

Keywords: adolescent, parent, game intervention, hpv prevention
dexamethasone iontophoretic patch for the treatment of pain associated with lateral epicondylitis

Conditions: Lateral Epicondylitis; (Tennis Elbow)

Summary: the objective of this study is to determine the safety and efficacy of a dexamethasone iontophoretic transdermal patch for the treatment of pain associated with lateral epicondylitis (tennis elbow).

detailed description: this trial is a randomized, double-blind, placebo-controlled, parallel-group trial in subjects diagnosed with lateral epicondylitis (tennis elbow). subjects entered into the trial will be assigned to one of four treatment groups. the total duration is up to 13 days of trial participation.

Eligibility criteria:
inclusion criteria: * subjects with onset of lateral epicondylitis symptoms no more than 12 weeks prior to study entry * female patients of childbearing potential must agree to use a medically accepted form of birth control. exclusion criteria: * subjects with other medical conditions/injuries of the elbow that would account for pain in the area * subjects who would require continuation of current pain medications during treatment * must not have received a prior corticosteroid injection for lateral epicondylitis in the affected arm
the mamma hitop study

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: the hitop ® 191 pnp an certified device licensed for the treatment of neuropathia. the home-based treatment is to be performed only in accordance with the approved investigational plan (cip) on subjects who have signed an informed consent form. device use is limited to the approved study investigators. the study is multicenter, randomized, double-blind, and placebo-controlled. primary objective: comparison of the change of paresthesias from baseline until end of therapy between the two patient groups, assessed by questionnaires secondary objectives: further symptoms of neuropathy as well as on health-related quality of life.


Eligibility criteria:
inclusion criteria: * - patients with histologically verified breast cancer and neoadjuvant or adjuvant treatment with a taxane derivate (e.g., paclitaxel, docetaxel): this group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9. * cumulative dose of at least 3 cycles * interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects * life expectancy of at least 3 months * eastern cooperative oncology group (ecog) performance status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying) * ability to walk (with or without aids) * european organisation for research and treatment of cancer (eortc) common toxicity criteria (ctc) peripheral sensory neuropathy grade 1 or 2 * intensity of paresthesias of \> 3/10 on the visual analog scale (vas) exclusion criteria: * - prevalent neuropathy of different etiology * serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators * epilepsy * minors or persons unable to give informed consent * current neurotoxic medication * implanted pacemakers or defibrillators * pregnancy * wounds in the area to be treated, acute local or systemic infection * peripheral arterial occlusive disease \> grade 2
pharmacodynamic study comparing the effects of two different forms of omeprazole (p07812) (completed)

Conditions: Intragastric Acidity

Summary: this randomized, crossover study is to evaluate the early effectiveness, defined as effect on intragastric ph during the first 4 hours after dosing, of zegerid, prilosec over-the-counter (otc) tablets, and placebo on the 4th day of treatment to inhibit acid secretion. additional purposes are to: 1. provide pharmacodynamic evidence comparing 24-hr inhibition of acid secretion on the 1st, 4th, and 11th days of dosing with each of the indicated treatments; 2. compare zegerid and prilosec otc for achieving their steady-state effects for controlling 24-hr gastric acidity at steady-state on the 4th and 11th day of dosing. 3. evaluate early effectiveness, defined as effect on intragastric ph during the first 4 hours after administration, of zegerid, prilosec otc tablets, and placebo on acid inhibition at steady-state when administered on the 11th day of dosing.

participants were randomized in a 3-way crossover design and received, in random order, zegerid otc capsules (20 mg omeprazole and 1100 mg sodium bicarbonate), prilosec otc tablets (20 mg-equivalent omeprazole), and placebo capsules. participants received each treatment for 11 days. there was a minimum of a 2-week washout period between treatment arms.

Eligibility criteria:
inclusion criteria: * male or non-lactating, non-pregnant female subjects who are 18-65 years of age. * physical examination findings within normal limits for age. exclusion criteria: * history of hypersensitivity, allergy or intolerance to omeprazole, or other proton pump inhibitors * history of peptic ulcer disease or other acid related gastrointestinal symptoms or heartburn with a frequency of more than one/month. * participation in any study of an investigational treatment in the 30 days before screening or participation in another study at any time during the period of this study * any significant medical illness that would contraindicate participation in the study * gastrointestinal disorder or surgery leading to impaired drug absorption * any abnormal screening laboratory value that is clinically significant in the investigator's opinion * current use of any prescription or otc medications that affect gastrointestinal function. * currently using or having a history of frequent use of antacids, otc or prescription (rx) histamine-2 (h2) receptor antagonists, or otc or rx use of proton pump inhibitors.

Keywords: gastric acid human experimentation
a phase 3 study to compare between ct-p41 and us-licensed prolia in postmenopausal women with osteoporosis

Conditions: Postmenopausal Women With Osteoporosis

Summary: this study is a double-blind, randomized, active-controlled, phase 3 study to compare efficacy, pharmacokinetics, pharmacodynamics, and safety of ct-p41 and us-licensed prolia in postmenopausal women with osteoporosis

this is a double-blind, randomized, active-controlled, phase 3 study to evaluate the efficacy, pk, pd, and safety including immunogenicity of ct-p41 compared with us-licensed prolia in postmenopausal women with osteoporosis. all patients will also receive daily supplementation containing at least 1,000 mg of elemental calcium and at least 400 iu vitamin d from randomization to eos visit and the data will be collected via patient's diary.

Eligibility criteria:
inclusion criteria: 1. women, 50 to 80 years of age, both inclusive. 2. body weight between 40.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth. 3. postmenopausal 4. bone mineral density t-score ≤ - 2.5 and ≥ - 4.0 at the lumbar spine (l1 to l4) as assessed by the central imaging vendor based on dual-energy x-ray absorptiometry(dxa) scan. 5. patients must have at least 3 vertebrae considered evaluable at the lumbar spine (l1 to l4) and at least 1 hip considered evaluable by dxa scan assessed by the central imaging vendor. patients with unilateral metal in hips that would be allowed for the other side of 1 evaluable hip are included. 6. patient with albumin-adjusted total serum calcium ≥ 8.5 mg/dl (≥ 2.125 mmol/l) at screening. exclusion criteria: 1. patient previously received denosumab, any other monoclonal antibodies, or biologic agents for osteoporosis 2. patient confirmed or suspected with infection of covid-19 at screening, or has contact with covid-19 patient within 14 days from screening 3. patient with history and/or presence of one severe or \> 2 moderate vertebral fractures as determined by central reading of lateral spine x-ray 4. patient with history and/or presence of hip fracture 5. patient with history and/or presence of hyperparathyroidism or hypoparathyroidism, irrespective of current controlled or uncontrolled status 6. patient with current hyperthyroidism (unless well controlled on stable antithyroid therapy) 7. patient with current hypothyroidism (unless well controlled on stable thyroid replacement therapy) 8. patient with history and/or presence of bone disease and metabolic disease (except for osteoporosis) that may interfere with the interpretation of the results
project smart automated pillbox study

Conditions: HIV/AIDS; Cocaine Use

Summary: the aim of this study is to examine the effect of mhealth tools on antiretroviral (art) adherence and persistence among hiv-infected individuals with co-occurring cocaine use disorders (cuds).

to conduct qualitative assessments using focus groups of people living with hiv (plh) who use cocaine and healthcare providers that will assess the acceptability, feasibility, facilitators and barriers of implementing mhealth interventions; and will aid in developing the final design and content of both automated and clinician feedback in preparation for designing a pilot feasibility study. to conduct a 12-week pilot feasibility rct among plh with co-occurring cuds that will examine the impact of mhealth tools (cellular-enabled smart pill boxes and cell phones) and feedback (no feedback vs. automated feedback vs. automated + clinician feedback) on primary (art adherence and persistence) and secondary outcomes (hiv viral suppression, cocaine use, retention in hiv care).

Eligibility criteria:
inclusion criteria: * age equal to or greater than 18 years * clinic-confirmed hiv diagnosis * currently prescribed or eligible for art * currently has insurance * self-reported cocaine use in the past 30 days * willing and able to use a cell phone and electronic pill box for the 12-week intervention exclusion criteria: * unable to provide informed consent * verbally or physically threatening to research staff * unable to communicate in either english or spanish
methylnaltrexone vs erythromycin for facilitating gastric emptying time in critically ill patients

Conditions: Gastroparesis

Summary: 42 patients admitted in icu with intolerance to enteral feeding (grv more than 250 ml) are recruited. all patients enter a primary acetaminophen absorption test study as baseline. serum levels of acetaminophen will be measured by florescence polarization method at 15,30,45,60,90,120,180,240,480 minutes after enteral administration of 975 mg acetaminophen. then the patients will be randomized to methylnaltrexone or erythromycin group.another acetaminophen absorption test with the same schedule will be done after the last dose of each drug.the area under the curve for acetaminophen blood level will be used to compare the effect of two studied drugs on gastric emptying time.


Eligibility criteria:
inclusion criteria: * patients admitted in intensive care unit in a university affiliated hospital * receiving continuous enteral feeding through a nasogastric tube * gastric residual volume more than 250 ml checked by aspiration technique exclusion criteria: * receiving the study drugs or metoclopramide within 24 hours of inclusion * known allergy to interventional drugs or acetaminophen * gastrointestinal bleeding or surgery on gi system within 24 hours of inclusion * crohn's disease * gi perforation or obstruction * short bowel syndrome * liver failure or 2 of the followings: * transaminase enzymes more than 3 times normal * prothrombin time more than 2 times normal * total bilirubin more than 3 times normal * patients on hemodialysis or crrt * hemodynamically unstable patients including: * mean arterial pressure less than 65 mmhg * infusion of inotropes and vasopressors * uncorrected acute blood loss; hemoglobin concentration less than 6.5 mg%. * documented or suspected pregnancy * obesity; actual body weight more than 1.5 times ideal body weight * myasthenia gravis. * opioid drug abuse

Keywords: gastroparesis erythromycin methylnaltrexone icu